
Successful Closure of Series A First Tranche for CHF 4.35M
23 December 2024
PRESS RELEASE
Lausanne, Switzerland – December 23, 2024 – Comphya SA, a pioneering medical technology company and the developer of CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction, is delighted to announce the successful closure of the first tranche of its Series A1 funding round. The total funding of CHF 4.35 million includes a combination of converted Convertible Loan and newly raised equity capital. This achievement strengthens Comphya’s financial position, enabling the continued advancement and expansion of its groundbreaking clinical trials.
The proceeds from this funding round will be instrumental in advancing our clinical trials across Australia, Brazil, and the United States, which have already demonstrated promising results.
“This new funding positions Comphya to accelerate the delivery of our groundbreaking solution to restore erectile function, while driving significant value for patients and stakeholders,” said Dr. Rodrigo Fraga, CEO of Comphya. “We deeply appreciate the trust and confidence our investors have placed in our vision and mission.”
Dr. Steve Swinson, Chairman of the Board, added, “This achievement is a testament to the unwavering dedication of our team, the trust of our investors, and the invaluable support of our key opinion leaders, including Prof. Arthur Burnett, Prof. Anthony Costello, Prof. Sidney Glina, and Dr. Phil Dundee. We extend our heartfelt gratitude to everyone who has contributed to Comphya’s success.”
We thank our investors, partners, and supporters for being part of this journey and invite you to stay tuned for more updates as we advance toward delivering life-changing solutions to patients worldwide.
Congratulations to the entire Comphya team on this important milestone! For more information, please visit www.comphya.com.
About CaverSTIM
CaverSTIM is the first implantable neurostimulator designed to restore erectile function. This innovative technology is primarily intended for patients who are non-responders to oral medications, such as post- prostatectomy patients. CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG) containing a rechargeable battery and electronics responsible for generating the electrostimulation signal. It is connected to an array of two electrodes (with multiple individual electrodes) to be implanted in the pelvic cavity, where they will activate and restore the nerves responsible for penile erection. The IPG is implanted subcutaneously in the lower abdomen and is remotely operated by external controllers. The clinician controller allows the medical expert to adjust and tailor the system parameters to best suit each patient. The patient controller enables the patient to activate the device and deliver electrical stimulation to the cavernous nerves with the aim of restoring their function.
About Comphya SA
Comphya is a medical device company based in Lausanne, Switzerland, developing CaverSTIM, the first implantable device to restore erectile function in patients non-responsive to oral drugs. Today, these patients resort to intrapenile injections or penile implants, the only available yet painful, problematic, and outdated therapies. Comphya’s patented solution offers a unique and superior treatment for erectile dysfunction. The company’s goal is to offer physiological sexual function and quality of life to large parts of the male population in great need.
The pilot clinical trial in Melbourne, Australia, is sponsored by Comphya Australia PTY LTD, a subsidiary of Comphya SA.
For more information, visit www.comphya.com
Contact
Comphya SA
Rodrigo Fraga-Silva, PhD
CEO & co-founder
Rodrigo.Fraga@comphya.com